Please login to the form below
multiple sclerosis
This page shows the latest multiple sclerosis news and features for those working in and with pharma, biotech and healthcare.
Bristol Myers Squibb announces positive trial results for treatment of MS
Bristol Myers Squibb (BMS) announced that analysis from two phase 3 trials of Zeposia (ozanimod) showed that early use of the treatment demonstrated cognitive benefits in people with relapsing multiple sclerosis
Latest news
-
Biogen and Happify Health team up to create digital platform for MS patients
Biogen and Happify Health have revealed plans for a new collaboration to support people living with multiple sclerosis (MS), with the companies aiming to provide a digital solution for patient education
-
Biogen and MedRhythms sign deal worth over $120m for digital therapeutics for MS patients
Biogen and MedRhythms have partnered in a new licence agreement to develop and commercialise an investigational prescription digital therapeutic, MR-004, that is focused on improving multiple sclerosis (MS) patients’ mobility
-
Roche shares new positive Ocrevus data for MS patients
Roche has shared new Ocrevus (ocrelizumab) data that demonstrates its benefit on disease progression and cognitive outcomes in primary progressive multiple sclerosis (PPMS) and secondary progressive MS (SPMS). ... Multiple sclerosis (MS) is a chronic
-
Novartis’ Kesimpta trial evaluates treatment of COVID-19 in MS patients
multiple sclerosis (RRMS) who have been treated with Kesimpta (ofatumumab). ... David Martin, chief executive officer, Multiple Sclerosis Trust: “Access to a range of different treatment options is important for people living with MS to manage their
-
MHRA grants approval for AstraZeneca’s Evusheld in the UK
This includes those patients diagnosed with blood cancers, those taking immunosuppressive drugs after an organ transplant, or for conditions including rheumatoid arthritis and multiple sclerosis.
More from news
Approximately 108 fully matching, plus 516 partially matching documents found.
Latest Intelligence
-
Making the case for embedding personalised healthcare in secondary care – what can pharma do to help?
If we take multiple sclerosis (MS) as a living example, we know that patient outcomes are better when patients have a key role to play in their ongoing treatment.
-
Behaviour change – a maze of decisions influenced by personal habits, experiences and intentions
She highlighted a Lucid Group initiative that improved the delivery of multiple sclerosis services after collaborating with specialist nurses and taking the time to understand their issues.
-
What Hemingway got right about patient communications
as multiple sclerosis and migraine, to monitor their health and track the success of their medication.
-
The search for treatments for Parkinson’s disease
and a decade as senior director of neurodegenerative diseases research at Merck Serono where he served as its leader for in vitro pharmacology in neurology, including in multiple sclerosis, Parkinson’s
-
Cortellis Drugs to Watch in 2020 report
of B and T cells outside the lymph nodes, to treat relapsing forms of multiple sclerosis. ... Despite the expectation that it will face intense competition in the crowded multiple sclerosis market, sales of $80m are forecast for this year, rising to
More from intelligence
Approximately 0 fully matching, plus 39 partially matching documents found.
Latest appointments
-
Ex-Roche CMO Sandra Horning joins Gilead’s board of directors
During her ten-year career at Roche, Horning helped to bring 15 new medicines to patients in a range of diseases, including cancer, multiple sclerosis, influenza and blindness. ... Sandra has significant industry expertise and vast experience in drug
-
Topas Therapeutics appoints chief development officer and chief medical officer
vice president, multiple sclerosis/neurology and immunology.
-
GW Pharmaceuticals strengthens research and development team
Knappertz has previously held several leadership positions including vice president of clinical development for multiple sclerosis, oncology and biosimilar products at Teva, and numerous clinical and medical roles at Bayer and
-
Sanofi appoints Bill Sibold to lead its Genzyme business
Previously head of Sanofi Genzyme’s multiple sclerosis, oncology and immunology organisation, Sibold has experience in leading global therapy launches.
-
Dr Irina Antonijevic joins vasopharm
Most recently, Dr Antonijevic served as global head of early development in neurology, multiple sclerosis and ophthalmology at Sanofi Genzyme in the US.
More from appointments
Approximately 0 fully matching, plus 25 partially matching documents found.
Latest from PMHub
-
Innovative Trials partners with MS Society
UK-based patient recruitment company announces its annual charity partnership in support of multiple sclerosis.
-
What does the future hold for clinical trial recruitment?
For example, new commonalities have been discovered between Type 1 diabetes, lupus, multiple sclerosis and rheumatoid arthritis, suggesting that drugs already in use to treat one autoimmune disease could be equally
-
MS Awareness Week - Matt's story
Matt is 31 and was diagnosed with multiple sclerosis, a chronic immune mediated inflammatory condition, two years ago.
-
Ten unbeatable reasons to explore a career with Oxford PharmaGenesis in 2022
Our triMS.online virtual event series connects a diverse global audience of healthcare professionals working in multiple sclerosis.
-
Innovative Trials
UK-based patient recruitment company announces its annual charity partnership in support of multiple sclerosis.
More from PMHub
Approximately 17 fully matching, plus 35 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- New Omicron sub-variants cause COVID-19 cases to rise in the UK
- Sanofi Global Health unveils new nonprofit Impact brand
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- NHS App to revolutionise digital health and care with major digital updates by 2023
- Pfizer announces commitment to achieve Net-Zero Standard by 2040
- Novartis announces positive phase 3 trial results for advanced oesophageal cancer
- The Power of AI in Medical Education
- First evidence-based guide launched to put patients at heart of digital innovations
- FDA grants Priority Review for Biogen and Eisai’s lecanemab for early Alzheimer’s disease
- New Swiss research reveals how Omicron evades the immune system
- Evoke Kyne Named Communiqué Communications Consultancy of the Year 2021
- Michael Grela Elected President of the Society for Health Communication
- First evidence-based guide launched to put patients at heart of digital innovations
- Roche shares new positive Ocrevus data for MS patients
- FDA grants Priority Review for Biogen and Eisai’s lecanemab for early Alzheimer’s disease
- A creative awakening – how pharma is bringing innovation to the patient journey
- Country report: The healthcare market in South Korea
- European Commission approves potential new treatment for Pompe disease
PMHub
Oncosec
OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...
Latest intelligence
- Five big changes in the healthcare comms landscape
- The world of healthcare has changed very greatly in the five years since The Difference Collective launched. Our agile model and talented team have enabled us to keep pace with...
- Early communications in Pharma: How effective pre-approval comms delivers launch success
- What communications are required for a successful launch...
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
